News

MCG Study is presented at the 84th JCS Conference

MCG Study is presented at the 84th Annual Scientific Meeting of the Japanese Circulation Society.
Under the influence of COVID-19, this meeting is decided to be held online.
Last week the presentation was recorded and it will be viewed by attendees during “the Week for JCS 2020,”  from July 27th to August 2nd.

The title of the study is

Feasibility study of artificial intelligence(AI) based Multifunction CardioGram(MCG) technology and its potential to help reduce cardiac death.

For details, please refer to JCS site at
http://www.congre.co.jp/jcs2020/en/index.html

The Asia Pacific Society of Cardiology(APSC) Congress 2020 is postponed

The Asia Pacific Society of Cardiology(APSC) Congress 2020 is postponed.

The meeting was originally scheduled in 12-14 March, but due to the effect of the epidemic of new Corona virus, it is postponed to the new schedule from 30th of July to 1st of August.

MCG study was accepted at the Asia Pacific Society of Cardiology(APSC) Congress 2020.
This congress is co-held with Japan Society of Cardiology (JSC).
The details of presentation is as follows.

Session Title: ACS/AMI (clinical/diagnosis) 3
Date: Friday, March 13, 2020 AM(The new schedule will be announced soon)
Abstract Title: Feasibility study of artificial intelligence(AI) based Multifunction CardioGram(MCG) technology and its potential to help reduce cardiac death.

For details of congress, please visit the following site.
http://www.congre.co.jp/apsc2020/

Premier Heart attended Clinica Manila@25 Health Tech Forum

Premier Heart joined a symposium  as a speaker in Clinica Manila@25 Health Tech Forum.

Clinica Manila, the forum discussing the preventive healthcare and advanced technologies was held on February, 27th, 2020 in Manila celebrating its 25th anniversary.

At the Forum, advanced technologies of preventive medicine and healthcare are introduced, and informative discussions are exchanged among doctors and suppliers regarding the application of the technologies to healthcare activities of the doctors.

Dr.Delizo, the organizer of the forum, commented about MCG: “It is useful technology of non-invasive and early detection. It enables to detect the change in patient condition at the early stage in easy way.”  He also expressed his vision of preventive healthcare by integrating these advanced technologies.

MCG study was accepted at the Asia Pacific Society of Cardiology(APSC) Congress 2020

A MCG study was accepted at the Asia Pacific Society of Cardiology(APSC) Congress 2020.
This congress is co-held with Japan Society of Cardiology (JSC) in 12-14 March, 2020 in Kyoto, Japan.
The details of presentation is as follows.

Session Title: ACS/AMI (clinical/diagnosis) 3
Date: Friday, March 13, 2020 AM
Abstract Title: Feasibility study of artificial intelligence(AI) based Multifunction CardioGram(MCG) technology and its potential to help reduce cardiac death.

For details of congress, please visit the following site.
http://www.congre.co.jp/apsc2020/

MCG was exhibited in the 60th Japan Ningen Dock Society

In 25-26 July, 2019, MCG was exhibited at the conference of  60th Japan Ningen Dock Society held in Okayama prefecture.　This  is the largest conference for health check up in Japan, attending more than 4,000 doctors and co-medicals.
MCG was co-exhibited with the wearable electrode “HITOE”, which was future electrodes without stress of adhesive gel and intertangling of leading codes.

MCG was presented by Dr.Amano at the ECG study group in Saitama

There was a lecture and presentation on MCG at the 15th Kita-Saitama ECG Study group held on May 27 in Fukaya, Saitama.
At the lecture, Dr. Tetsuya Amano(MD, PhD) , a professor of Aichi Medical University, gave a lecture on non-invasive examination and MCG for cardiovascular disease.
In the lecture, he explained it is important to evaluate the functional significant stenosis of the entire heart using SYNTAX score and FFR, etc when identifying cardiovascular disease.
Also he talked about expectations for MCG as a non-invasive alternative to invasive tests such as CTA and CAG, which are not recommended to the patients without symptoms.

In addition, Dr. Noboru Kujirai of Kagohara Hospital introduced cases of MCG. He explained a case about the patient with significantly higher MCG scores after PCI, and a case where restenosis was found in-stent with moderate MCG scores.

This lecture was very valuable for all audience to deepen their understanding about MCG.

MCG study is presented in ACC(American College of Cardiology) Asia

A  MCG study was accepted and presented at the Conference of ACC (American College of Cardiology ) Asia in December 2018.

The study was conducted in Myanmar. 30 patients (MCG score ≥ 4 ) were enrolled and compared the MCG results with the CAG results (75%-100% stenosis were positive).

The Average MCG score of CAG positive group was 7.0 and negative group was 5.4 (p<0.01). MCG cut off was 6, and it shows sensitivity:76.5%, specificity:69.2%, PPV76.5%, NPV69.2%, accuracy:73.3%(P<0.05).

The study concluded MCG showed high sensitivity and specificity, and MCG is effective as a noninvasive device for detection of severe IHD in Myanmar where catheterization facilities and doctors are very limited.

Please refer to the abstract from here.